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Deﬁciency of 3-methylcrotonyl-CoA carboxylase (MCC) results in elevated excretion of 3-methylcrotonylglycine
(3-MCG) and 3-hydroxyisovaleric acid (3-HIVA). MCC is a heteromeric mitochondrial enzyme comprising biotin-
containing a subunits and smaller b subunits, encoded by MCCA and MCCB, respectively. Mutations in these
genes cause isolated MCC deﬁciency, an autosomal recessive disorder with a variable phenotype that ranges from
severe neonatal to asymptomatic adult forms. No reported patients have responded to biotin therapy. Here, we
describe two patients with a biochemical and, in one case, clinical phenotype of MCC deﬁciency, both of whom
were responsive to biotin. The ﬁrst patient presented at 3 months with seizures and progressive psychomotor
retardation. Metabolic investigation at 2 years revealed elevated excretion of 3-MCG and 3-HIVA, suggestingMCC
deﬁciency. High-dose biotin therapy was associated with a dramatic reduction in seizures, normalization of the
electroencephalogram, and correction of the organic aciduria, within 4 weeks. MCC activity in ﬁbroblasts was
25% of normal levels. The second patient, a newborn detected by tandem-mass-spectrometry newborn screening,
displayed the same biochemical phenotype and remained asymptomatic with biotin up to the age of 18 months.
In both patients, sequence analysis of the complete open reading frames of MCCA and MCCB revealed hetero-
zygosity for MCCA-R385S and for the known polymorphic variant MCCA-P464H but revealed no other coding
alterations. MCCA-R385S is unusual, in that it has a normal amount of MCCa protein but confers no MCC
activity. We show that MCCA-R385S, but not other MCCA missense alleles, reduces the MCC activity of cotrans-
fected MCCA–wild-type allele. Our results suggest that MCCA-R385S is a dominant negative allele and is biotin
responsive in vivo.
Introduction
3-methylcrotonyl-CoA carboxylase (MCC [Enzyme
Commission number 6.4.1.4]) is a biotin-dependent en-
zyme that catalyzes the fourth step in the leucine cata-
bolic pathway. It carboxylates 3-methylcrotonyl-CoA to
3-methylglutaconyl-CoA in an ATP-requiring reaction
that uses bicarbonate as the source of the carboxyl group
(Sweetman and Williams 2001).
MCC is a member of the family of biotin-dependent
carboxylases, a group of enzymes with diverse meta-
bolic functions but common structural features (Samols
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et al. 1988; Wolf 2001). In addition to MCC, there are
three other biotin-dependent carboxylases in humans:
propionyl-CoA carboxylase (PCC), pyruvate carbox-
ylase, and acetyl-CoA carboxylase (Samols et al. 1988;
Wolf 2001). Biotin is covalently bound to the apocar-
boxylases by holocarboxylase synthetase (HCS [Gen-
Bank accession number BC060787]) and, after prote-
olytic degradation of the active holocarboxylase into
short biotinyl peptides or biocytin, it is released by bio-
tinidase, enabling the recycling of biotin (Wolf 2001).
MCC deﬁciency is caused either by defects of the
MCC enzyme itself or by deﬁcient activity of the en-
zymes involved in the metabolism of its cofactor bio-
tin—that is, the enzymes HCS or biotinidase—deﬁci-
ences of which cause multiple carboxylase deﬁciency.
Isolated biotin-resistant MCC deﬁciency (also known
as “methylcrotonylglycinuria” [MIM 210200 and
210210]) is inherited as an autosomal recessive trait
(Sweetman and Williams 2001). The clinical phenotype
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is highly variable. Some patients present in the neonatal
period with seizures and hypotonia (Bannwart et al.
1992; Lehnert et al. 1996); others are asymptomatic
adult women discovered only by detection of abnormal
metabolites in the neonatal-screening samples from
their healthy babies (Gibson et al. 1998). Most patients
are asymptomatic until an episode of acute metabolic
decompensation after intercurrent illness in early child-
hood, which leads to their diagnosis. These patients usu-
ally respond to intravenous ﬂuids and the cessation of
protein feeding and are asymptomatic between epi-
sodes. Some children have been placed on a leucine-
restricted diet supplemented with oral L-carnitine, but
the efﬁcacy of this approach is unproven. In contrast to
patients with multiple carboxylase deﬁciency due to
HCS or biotinidase deﬁciency, no reported patient has
been biotin-responsive, deﬁned as showing a signiﬁcant
clinical and/or biochemical improvement in response to
oral administration of biotin at doses of 1–2 mg/kg/d
or higher.
Patients with MCC deﬁciency have a characteristic
organic aciduria with greatly increased excretion of 3-
hydroxyisovaleric acid (3-HIVA) and 3-methylcroto-
nylglycine (3-MCG), usually in combination with severe
secondary carnitine deﬁciency. In addition, acyl-CoA
derivatives accumulate and are trans-esteriﬁed to acyl-
carnitine esters; the major abnormal metabolite, 3-hy-
droxyisovalerylcarnitine, is found in blood and urine
(Sweetman and Williams 2001). It is surprising that
MCC deﬁciency appears to be the most frequent organic
aciduria detected in tandem mass spectrometry (TMS)
newborn-screening programs in North America (Naylor
and Chace 1999; Koeberl et al. 2003), Europe (Roscher
et al. 2000; Schulze et al. 2003), and Australia (Wilcken
et al. 2003).
Isolated MCC deﬁciency can be conﬁrmed by dem-
onstration of deﬁcient MCC activity in the presence of
normal activity of another biotin-dependent carboxyl-
ase in cultured skin ﬁbroblasts or in isolated lympho-
cytes. MCC activity in cultured ﬁbroblasts of patients
is usually !2% of the mean control value. Two patients
with higher residual activity, varying from 4% to 12%,
in cultured ﬁbroblasts have been reported elsewhere
(Tuchman et al. 1993; Wiesmann et al. 1998). No cor-
relation between the level of residual enzyme activity
and clinical presentation has been observed.
Bovine MCC has a size of ∼835 kD and appears to
comprise six heterodimers: (ab)6 (Lau et al. 1980).
MCC is predominantly localized to the inner mito-
chondrial membrane. Like PCC, MCC is composed of
larger a-subunits, which covalently bind biotin, and
smaller b-subunits, encoded by the MCCA (MCCC1
[GenBank accession number BC004214]) and MCCB
(MCCC2 [GenBank accession number BC065027])
genes, respectively, which have been cloned and char-
acterized (Baumgartner et al. 2001; Gallardo et al.
2001; Holzinger et al. 2001). To date, 1 functionally
neutral polymorphic variant, 9 functionally signiﬁcant
mutant MCCA alleles, and 13 functionally signiﬁcant
mutant MCCB alleles have been reported in probands
with severe MCC deﬁciency (Baumgartner et al. 2001;
Gallardo et al. 2001; Holzinger et al. 2001; Obata et
al. 2001; Desviat et al. 2003). Several affected sibs of
symptomatic patients have been clinically normal (Bee-
mer et al. 1982; Jurecki and Packman 1992; Mourmans
et al. 1995), suggesting that the genotypes at theMCCA
and MCCB loci are not the sole determinants of the
clinical phenotype.
One of the identiﬁed missense alleles, MCCA-R385S,
is unusual in that it is the only one of seven missense
alleles detected in six MCCa-deﬁcient patients for
whom protein-blot analysis of ﬁbroblast homogenates
shows the presence of MCCa protein (i.e., shows cross-
reactive material [CRM]) (Baumgartner et al. 2001;
Gallardo et al. 2001). Indeed, these studies suggest that
the amount of MCCa protein in ﬁbroblasts from a pa-
tient homozygous for theMCCA-R385S allele is normal
or greater than normal, whereas six other MCCA mis-
sense alleles had little or no detectable CRM (Baum-
gartner et al. 2001). MCCA-R385S appears to be the
most frequent allele found in MCC-deﬁcient patients of
German origin. Of seven such patients, one is homo-
zygous and six are compound heterozygous for MCCA-
R385S (M.R.B. and M.F.D, unpublished data).
Here, we describe two patients with elevated excre-
tion of 3-MCG and 3-HIVA and with partial deﬁciency
of MCC, one of whom has severe neurological symp-
toms. Both patients showed evidence of biotin respon-
siveness and were heterozygous for MCCA-R385S and
the polymorphic variantMCCA-P464H.We provide ev-
idence that MCCA-R385S is a dominant negative allele
leading to biochemical abnormalities and clinical symp-
toms in heterozygous individuals and that it is respon-
sive to pharmacologic doses of biotin in vivo.
Subjects and Methods
Case Reports
Patient 1 (MCC047).—This boy was the second child
of healthy, nonconsanguineous German parents. At the
age of 3 wk, he developed infantile spasms. Electroen-
cephalogram (EEG) results showed hypsarrhythmia at
age 3 mo. Routine cerebrospinal-ﬂuid and brain mag-
netic resonance imaging (MRI) investigations were nor-
mal. Therapeutic trials with vitamin B6 and vigabatrin
did not lead to clinical improvement. At 2 years of age,
he presented with severe psychomotor retardation, per-
sistent infantile spasms, and hypsarrhythmia. MRI of
the brain showed signiﬁcant frontal and parietal cerebral
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Table 1
Effect of Biotin Substitution on 3-HIVA and 3-MCG Concentration in Urine
SUBJECT AND
BIOTIN SUBSTITUTION
TIME AFTER
LEUCINE LOADa
(h)
CONCENTRATION IN URINE OFb
(mmol/mol creatinine)
3-HIVA 3-MCG
MCC047:
No biotin … 276 653
10 mg/d for 7 d … 358 300
40 mg/d for 7 d … 135 44
40 mg/d for 3 more wk … 17 9
Father of MCC047:
No biotin … 26 ND
Mother of MCC047:
No biotin … 24 ND
MCC048:
No biotin Before load 105 2.2
No biotin 0–2 183 12
No biotin 2–4 956 33
No biotin 4–6 794 35
No biotin Before load 100 ND
5 mg/kg with leucine at 0 h 0–2 368 6.2
No biotin 2–4 471 25
No biotin 4–6 335 12
Controls:
No biotin … !18 ND
a Patient MCC048 was given a leucine load of 150 mg/kg with and without a si-
multaneous biotin load, and urine was collected in three portions after the load.
b ND p not detectable.
atrophy mainly of the white matter. Metabolic investi-
gations revealed elevated excretion of 3-HIVA and 3-
MCG without other abnormalities, suggesting MCC de-
ﬁciency (table 1). Biotin treatment with 10 mg/d had no
clinical or biochemical effect. An increase in the dose to
40 mg/d (2.7 mg/kg) was associated with dramatic re-
duction of seizure frequency. Within 4 wk, the EEG
markedly improved, showing the disappearance of hyps-
arrhythmia, and the organic aciduria became virtually
normal (table 1). On a biotin regimen (50 mg/d) and a
protein-restricted diet (0.8 g/kg/d, introduced at age 2.5
years), the patient showed no further progression of
symptoms, and excretion of 3-HIVA and 3-MCG com-
pletely normalized. Biotinidase activity in plasma was
normal. At 7 years of age, he was seizure free on a
protein-restricted diet (0.8 g/kg/d) and a regimen of vi-
gabatrin and biotin (50 mg/d), and his EEG was unre-
markable. Formal psychometrics were not obtained.
Patient 2 (MCC048).—This boy was the second child
of healthy, nonconsanguineous Greek parents. His pre-
and postpartum history was unremarkable except for a
hyperbilirubinemia requiring phototherapy. He was re-
ferred at age 5 wk because of elevated 3-hydroxyiso-
valerylcarnitine detected by TMS newborn screening.
Urinary organic acid analysis displayed elevated 3-
HIVA and trace amounts of 3-MCG with no other ab-
normalities (table 1). To test for a suspected defect in
leucine catabolism, the patient received an oral leucine
load (150 mg/kg). This challenge resulted in transient
hyperammonemia (up to 134 mmol/L; normal ! 80) and
in a signiﬁcant increase in urinary excretion of 3-HIVA
and 3-MCG (table 1) that was partially suppressed by
simultaneous administration of biotin (5 mg/kg) (table
1), suggesting in vivo biotin responsiveness similar to
that of patient MCC047. Ten other infants who were
referred because of elevated isovalerylcarnitine detected
by TMS were similarly tested but showed normal or-
ganic acid excretion before and after leucine loading
(data not shown). At 18 mo of age, patient MCC048
received biotin (5 mg/kg) and carnitine (50 mg/kg) and
was developing normally. His urinary excretion of 3-
HIVA and 3-MCG remained elevated (334 and 11.7
mmol/mol creatinine, respectively). Samples from the
parents of patient MCC048 were not available. In-
formed consent for this study was obtained from the
parents of both patients.
Cell Cultures and Carboxylase Assays
Skin ﬁbroblasts were cultured in a standard medium
containing 10% fetal calf serum (FCS). The biotin con-
centration of this medium, supplied by the natural biotin
content of FCS, was 9 nmol/L, or 5-fold the mean nor-
mal plasma biotin concentration in humans (1.80 
Baumgartner et al.: Biotin-Responsive MCC Deﬁciency 793
0.84 nmol/L, range 0.65–4.83 nmol/L; ) (Suor-np 126
mala et al. 1997).We prepared a biotin-depletedmedium
by replacing FCS with newborn calf serum (NBCS),
which resulted in a ﬁnal biotin concentration of 0.1
nmol/L. To obtain physiological biotin concentration,
we supplemented the low-biotin medium with 2.0 nmol/
L biotin and, to obtain a high-biotin medium, with 10
mmol/L biotin (i.e., 5,000 times higher than normal
plasma levels).
The activities of PCC and MCC were assayed in ﬁ-
broblast homogenates by measurement of the incorpo-
ration of 14C-bicarbonate into acid-nonvolatile prod-
ucts, by methods established elsewhere (Suormala et al.
1985).
Mutation Analysis by RT-PCR and Genomic PCR
We extracted RNA and genomic DNA from skin ﬁ-
broblast cultures between 5–15 passages, using RNA
and DNA isolation kits from Qiagen. We performed RT-
PCR using 2–5 mg of total cellular ﬁbroblast RNA and
a cDNA cycle kit (Invitrogen) in accordance with the
manufacturer’s recommendations. To search for muta-
tions, we used primer pairs in the 5′- and 3′-UTR to
amplify by RT-PCR the complete MCCA or MCCB
ORF, as described elsewhere (Baumgartner et al. 2001).
We used the same approach to amplify the complete
ORF of the HCS gene. The PCR products were gel pu-
riﬁed and were sequenced directly.
To conﬁrm mutations identiﬁed in RT-PCR products,
we ampliﬁed a genomic fragment containing the cor-
responding exon, using ﬂanking intronic primers, and
sequenced the PCR product directly (Baumgartner et al.
2001). All PCR reactions (50 ml) contained primers (100
ng of each), standard PCR buffer (Gibco-BRL), dNTPs
(200 mM), and Taq polymerase (2.5 U) (Gibco-BRL).
The sequences of all primers are available on request.
Construction of Wild-Type and Mutant MCCA
Expression Vectors
We cloned the full-length human MCCA (51 to
2275, where 1 is the A nucleotide of the initiation
methionine codon) cDNA into a mammalian expression
vector (pTracer-CMV2 [Invitrogen]) at the EcoRI sites,
as described elsewhere (Baumgartner et al. 2001). To
introduce R385S, A289V, L437P, and P464H into
MCCA, we harvested an 896-bp ACCI fragment from
RT-PCR–ampliﬁed cDNA from individuals with these
variants and subcloned the fragment into the wild-type
MCCA construct, as described elsewhere (Baumgartner
et al. 2001). The pTracer-CMV2 vector contains a green
ﬂuorescent protein (GFP) gene fused to the Zeocin-re-
sistance gene. We sequenced all constructs in both di-
rections to validate the sequences.
Transfections
For expression studies, we electroporated the indicated
constructs into SV40T-transformed skin ﬁbroblasts from
a patient homozygous for MCCA Q421fs(1), as de-
scribed elsewhere (Braverman et al. 1997; Baumgartner
et al. 2001). These cells have no detectableMCCactivity.
The cells were harvested after 72 h and were assayed
for MCC and PCC activities. All transfections were per-
formed in duplicate. Transfection efﬁciency was assessed
by scoring a subset of cells in each transfection for the
presence of GFP and ranged from 10%–20% in these
experiments. Transformed ﬁbroblasts from an unaf-
fected individual were used as control.
Allelic Variation in MCCA Expression
We used the MCCA SNP c.1391CrA, which results
in the P464H amino acid change, to quantitate allele-
speciﬁc transcripts by means of single-nucleotide primer
extension (SnuPE) and laser-induced ﬂuorescence cap-
illary electrophoresis, as described elsewhere (Ma´tya´s et
al. 2002). This method takes advantage of distinct mo-
bilities of SnuPE products with different nucleotides in-
corporated at their 3′ ends and has been independently
shown to yield highly quantitative results (Ma´tya´s et al.
2002; Yan and Zhou 2003).
Results
Carboxylase Activities
MCC activity in crude homogenates of ﬁbroblasts cul-
tured in standardmediumwas reduced below the normal
range in patients MCC047 and MCC048, with an av-
erage of 26% and 36% of the mean control value, re-
spectively (ﬁg. 1). This residual activity is greater than
that in ﬁbroblasts from four typical CRM MCC-deﬁ-
cient patients (0%–1% of mean control value) (ﬁg. 1)
but is less than that in ﬁbroblasts from six heterozygotes
for CRMMCCA orMCCB alleles (72%–118%of con-
trol). The activity of another biotin-dependent carbox-
ylase, PCC, was within the normal range in patients
MCC047 and MCC048, indicating that the deﬁciency
of MCC is speciﬁc. Moreover, the ratio of MCC to PCC
activity was consistently below the control range in
both patients (MCC047: mean 0.19, range 0.18–0.19;
MCC048: mean 0.24, range 0.19–0.32; 13 controls:
mean 0.52, range 0.41–0.75). Fibroblast MCC activ-
ity levels from the father and the mother of patient
MCC047 were both at the low end of the normal range
(52% and 63% of the mean control value, respectively).
However, the ratio of MCC to PCC activity was con-
sistently below the control range in the father, who was
also heterozygous for MCCA-R385S, whereas the ratio
was normal in three of four experiments in the mother
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Figure 1 MCC and PCC activities in ﬁbroblasts from patient MCC047 and his parents, from patient MCC048, from four typical CRM
MCC-deﬁcient patients (probands 009, 010, 012, and 013 in Baumgartner et al. 2001), and from 13 control cell lines grown in standard FCS-
based medium with a biotin concentration of 9 nmol/L. The indicated activities are the mean and range (vertical lines) of four individual
experiments each with duplicate determinations. Values in the CRM MCC-deﬁcient patients are the mean and range of activities obtained in
four different patients. Control values represent the mean and range of activities obtained in 13 different cell lines.
(father of MCC047: mean 0.29, range 0.24–0.36; mother
of MCC047: mean 0.4, range 0.34–0.42).
To determine whether the extent of the MCC deﬁ-
ciency in our patients’ ﬁbroblasts was inﬂuenced by the
biotin concentration of the medium, we cultured the cells
for one passage (17–27 d) in either biotin-depleted (0.1
nmol/L) or high-biotin (10,000 nmol/L) medium (table
2). After one passage in the biotin-depleted medium,
MCC activities in ﬁbroblasts from patients MCC047
and MCC048 and from the parents of MCC047 were
decreased to 24%–35% of activity in the high-biotin
medium. A similar decrease occurred in control cells.
Even after four passages in the low-biotinmedium,MCC
activity in the cells from patient MCC047 was decreased
to only 27% (data not shown). Cells from patients with
HCS deﬁciency exhibit a dramatic decrease in MCC ac-
tivity when cultured in biotin-depleted medium (Suor-
mala et al. 1997), which makes it unlikely that an ab-
normality of this enzyme contributes to our patients’
biochemical phenotype. Furthermore, MCC and PCC
activities in cells cultured in mediumwith a physiological
concentration of biotin (2.1 nmol/L) were similar to
those in cells cultured in the high-biotin medium. In-
creasing the biotin concentration to 100 mmol/L in the
medium failed to increase the activities of MCC further
(data not shown). Thus, we found no evidence for an
increased biotin requirement as the cause of the low
MCC activity in the patients’ ﬁbroblasts.
Normal kinetics of MCC activity were obtained in
crude homogenates of ﬁbroblasts from MCC047 when
they were assayed with varying concentrations of bi-
carbonate, 3-methylcrotonyl-CoA, ATP, magnesium,
and chloride in the assay mixture (results not shown).
These results indicate that a decreased afﬁnity of MCC
for these assay components is highly unlikely to be the
cause of the reduced activity in this patient. Despite these
results, the ratio of MCC to PCC activity in ﬁbroblasts
from patient MCC047, his father, and patient MCC048
was reproducibly below the control range, whereas the
ratio in ﬁbroblasts from the mother of patient MCC047
was within the range of controls (table 2).
Mutation Analysis
Despite high residual MCC activity in vitro, the pat-
tern of metabolic abnormalities in our patients suggested
a partial defect at the level of MCC in vivo. To inves-
tigate this possibility, we sequenced the entire ORF of
MCCA and MCCB in the products of RT-PCR ampli-
ﬁcation of ﬁbroblast RNA in patients MCC047 and
MCC048. We found that both patients and the father
of patient MCC047 are heterozygous for an ArC trans-
version at position 1155, creating a new restriction site
for NheI (GCTAGArGCTAGC) and substituting a
serine for an arginine at position 385 (MCCA-R385S).
Patients MCC047 and MCC048 and the mother of
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Figure 2 Detection of the MCCA 1155ArC (R385S) mutation
in the MCC047 nuclear family. The 327-bp fragment ampliﬁed from
genomic DNA (MCCA exon 11) was subjected to digestion withNheI.
The wild-type fragment is not cut, whereas the R385S fragment is
cleaved into fragments of 130 bp and 197 bp.
Table 2
Activities of 3-MCC and PCC in Fibroblasts Grown in NBCS-Based Low-Biotin Medium (0.1 nmol/L) and in
the Same Medium Supplemented with Physiological (2.1 nmol/L) and High (10 mmol/L) Biotin
Concentrations
SUBJECT AND
BIOTIN IN MEDIUM
(nmol/L)
CARBOXYLASE ACTIVITIESa
(pmol/min/mg protein)
MCC PCC MCC/PCC Ratio
MCC047:
.1 31.5 375 .08
2.1 102 628 .16
10,000 100 638 .16
Father of MCC047:
.1 42.0 280 .15
2.1 121 446 .27
10,000 130 498 .26
Mother of MCC047:
.1 61.2 315 .20
2.1 176 500 .35
10,000 177 472 .38
MCC048:
.1 30.4 283 .11
2.1 120 603 .20
10,000 128 603 .21
21 controls, mean  SD (range):
.1 145  57 (70.4–292) 494  172 (300–889) .3  .08 (.17–.43)
10,000 340  130 (140–606) 694  246 (347–1,246) .5  .13 (.29–.85)
a Values are the mean of duplicate determinations within one experiment.
MCC047 are heterozygous for the previously described
neutral polymorphism 1391CrA (MCCA-P464H). The
father of MCC047 does not carry this polymorphism.
From this, we conclude that the MCCA-R385S allele
encodes a proline at codon 464. We found no other
sequence abnormalities over the entire length of the
MCCA and MCCB ORFs. We conﬁrmed these results
by direct sequencing of PCR-ampliﬁed genomic DNA
followed by digestion with NheI (ﬁg. 2). We also am-
pliﬁed and sequenced all MCCA exons and ﬂanking in-
tronic sequences in patient MCC047 and found no ad-
ditional mutations. Because biotin responsiveness in
other carboxylase-deﬁcient patients has been shown to
be due to deﬁciency of HCS, we also RT-PCR ampliﬁed
and sequenced the entire HCS ORF and found no se-
quence abnormalities.
Expression Studies
In previous experiments, we showed that MCCA-
R385S and several other MCCA missense alleles con-
ferred no MCC activity when transfected into MCCA
null cells (Baumgartner et al. 2001). To test if MCCA-
R385S also has a dominant negative inﬂuence on the
activity of MCCA wild type, we cotransfected both al-
leles into an SV40T-transformed MCCa-deﬁcient ref-
erence cell line and measured MCC activity 72 h later.
In two separate experiments, cotransfection of MCCA
wild-type allele with vector without an insert restored
MCC activity to 55% of nontransfected control ﬁbro-
blasts, whereas cotransfection of MCCA wild type with
MCCA-R385S restored MCC activity to 25%—that is,
to ∼50% of that obtained with wild type coexpressed
with vector without an insert. In contrast, cotransfection
of MCCA wild type with either MCCA-A289V or
MCCA-L437P restored MCC activity to the same level
as that obtained with wild type coexpressed with vector
without insert (ﬁg. 3). Thus, the reduction of MCC ac-
tivity is speciﬁc for MCCA-R385S. We repeated the ex-
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Figure 3 The effect of coexpression of MCCA missense alleles and wild-type MCCA. MCC-deﬁcient cells were cotransfected with wild-
type MCCA plus MCCA alleles with the indicated missense mutation. Activities represent mean and range obtained in two individual experiments.
MCC activity of cells cotransfected with wild-type MCCA and a vector without an insert was set at 100%.
periment using the MCCA–wild-type construct with his-
tidine instead of a proline at codon 464 (MCCA-P464H)
with similar results. Thus, the dominant negative effect
of MCCA-R385S when coexpressed with the wild-type
allele is independent of the P464H polymorphism.
Allelic Variation in Expression
Recent reports have shown variation in expression of
apparently wild-type alleles, for as many as 50% of all
genes (Yan et al. 2002; Lo et al. 2003). This variation
in expression ranges 2–4 fold, segregates with the al-
lele, and could markedly affect the consequences of het-
erozygosity for a recessive loss-of-function mutation on
the other allele. To determine if allele-speciﬁc variation
in expression was playing a role in the manifestation of
MCC deﬁciency in individuals heterozygous for MCCA-
R385S, we used a ﬂuorescent dideoxy-terminator–based
method to distinguish the mRNA products of individual
alleles in patient MCC047, his mother, and patient
MCC048, by use of the MCCA-P464H polymorphism
to mark the alleles. In patient MCC047 and his mother,
both alleles were expressed at equal levels, whereas, in
patient MCC048, the expression of the MCCA-S385
allele (marked by P464 in cis) was reduced to ∼40% of
that of the wild-type MCCA allele (marked by H464)
(ﬁg. 4). Thus, in these heterozygous individuals, we
found no evidence for signiﬁcant variation in expression
of the MCCA wild-type allele.
Discussion
Both patients described here showed a persistent char-
acteristic organic aciduria, with elevated excretion of 3-
MCG and 3-HIVA suggesting MCC deﬁciency. One suf-
fered from severe neurological symptoms starting at the
age of 3 wk, whereas the other was an asymptomatic
newborn detected by TMS newborn screening. In patient
MCC047, excretion of the disease-speciﬁc metabolite 3-
MCG was within the range found in patients with severe
MCC deﬁciency (Sweetman and Williams 2001); in pa-
tient MCC048, urinary 3-MCG was lower but was per-
sistently elevated. Enzymatic determination of MCC ac-
tivity in cultured ﬁbroblasts revealed a partial but
speciﬁc MCC deﬁciency. In both patients, residual ﬁ-
broblast MCC activity was not abnormally sensitive to
biotin depletion, nor was it enhanced by addition of high
concentrations of biotin to the medium. These results
rule out HCS deﬁciency as the cause of reduced MCC
activity and are consistent with the clinical features and
the persistent organic aciduria in our patients.
Our mutation analysis of the MCCA and MCCB
genes revealed that both patients are heterozygous for
a previously described missense mutation, MCCA-
R385S, and a known polymorphism, MCCA-P464H
(Obata et al. 2001). In earlier studies, we showed that
MCCA-R385S confers no MCC activity when trans-
fected into reference MCCa-deﬁcient cells (Baumgart-
ner et al. 2001). We found the MCCA-R385S allele in
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Figure 4 Allelic variation in MCCA expression. A sample of electrospherograms of SnuPE products from the sense strand of RT-PCR–
ampliﬁed DNA from patient MCC047 and his mother and from patient MCC048. Mobility of tetramethyl-6-carboxyrhodamine (TAMRA)–
labeled allele-speciﬁc SnuPE is shown for the MCCA polymorphic variant c.1391CrA (MCCA-P464H). Each peak represents a speciﬁc allelic
variant. Allele 1 with an A nucleotide at c.1391 encodes 464H, whereas allele 2 with a C nucleotide at c.1391 encodes 464P and the functionally
signiﬁcant 385S. The relative quantiﬁcation of each allele represents the mean and range of two independent experiments performed on ﬁbroblast
RNA.
1 of 132 control chromosomes from white individuals
(Baumgartner et al. 2001).
An arginine at position 385 (or the corresponding
position) is strictly conserved in mammalian, plant, fun-
gal, and bacterial carboxylases (Samols et al. 1988; Ji-
trapakdee and Wallace 1999), and the corresponding
residue in the biotin carboxylase domain of Escherichia
coli acetyl-CoA carboxylase (R338) has been shown to
be part of a positively charged pocket for bicarbonate
binding (Thoden et al. 2000).
To explain the biochemical abnormalities in both pa-
tients and the clinical phenotype in patient MCC047,
we hypothesize a dominant negative inﬂuence of the
mutant S385 MCCa subunit on MCC activity. A dom-
inant negative effect of the protein product of a mutant
allele usually involves homomeric or heteromeric pro-
teins. Typically, the protein product of a dominant neg-
ative allele is functionally inactive and has the added
property of inhibiting the activity of the protein product
of the normal allele (Herskowitz 1987). To achieve this,
the dominant negative mutant protein product must be
stable and must be able to assemble into the normal
multimeric protein complex. MCCa S385 fulﬁlls these
criteria. In contrast to the protein products of all other
MCCA missense alleles, the MCCa S385 protein is sta-
ble (Baumgartner et al. 2001; Gallardo et al. 2001). On
protein-blot analysis using avidin alkaline phosphatase
as a probe, MCCa S385 accumulates to levels equal to
or greater than normal (Baumgartner et al. 2001). De-
spite this, expression studies clearly show that the
MCCa S385 is catalytically inactive (Baumgartner et al.
2001; Desviat et al. 2003). Moreover, the results of our
cotransfection experiments show that expression of
MCCa S385 but not of two other MCCA missense al-
leles inhibits the function of coexpressed wild-type
MCCa protein. Taken together, these data strongly sup-
port our hypothesis of a dominant negative effect of
MCCa S385 on the wild-type protein and thus onMCC
activity.
Additional evidence comes from the recent studies of
Sloane and Waldrop (2004), who used the puriﬁed
homodimer of the biotin carboxylation subunit of E.
coli acetyl CoA carboxylase to study kinetic properties
of mutant proteins. They showed that E. coli biotin
carboxylase-R338S, the missense mutant corresponding
to MCCA-R385S, exhibited a dominant negative effect
on the function of the wild-type active site, by negative
cooperativity with respect to bicarbonate concentration
(Sloane and Waldrop 2004). Furthermore, they pre-
sented evidence that the degree of negative cooperativity
is decreased with increasing concentrations of biotin.
These data support our hypothesis of a dominant neg-
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ative effect of MCCa S385 on the wild-type protein and
thus on MCC activity.
The presence of a functionally signiﬁcant mutation in
the second allele would also explain the reduced MCC
activity in our patients. However, we searched exten-
sively for a functional mutation on the second allele by
RT-PCR of mRNA of the entire MCCA ORF, as well
as by ampliﬁcation and sequencing of all MCCA exons
and ﬂanking intronic splice sites from genomic DNA.
By direct sequencing of the RT-PCR product, we could
clearly see that both patients are heterozygous for the
R385S change, which indicates that the second allele
produced a stable mRNA transcript, but we found no
molecular abnormalities in the MCCA transcript or
structural gene that could explain a reduction in the
function of its protein product. For all of these reasons,
we concluded thatMCCa S385 has a dominant negative
effect on the wild-type protein.
How do we explain the lack of biochemical abnor-
malities in other R385S heterozygotes (e.g., the father
of MCC047)? The R385S-MCCA heterozygotes with
normal urinary organic acids who we have studied were
all adults. Thus, one possible explanation is that the
metabolic demands on the pathway are lesser in adults
than in infants and children. This would also be con-
sistent with the identiﬁcation of asymptomatic adults
with severe MCC deﬁciency (Gibson et al. 1998; Baum-
gartner et al. 2001). An alternative and nonexclusive
explanation for the phenotypic variation in MCCA-
R385S heterozygotes has to do with the amount of func-
tional MCCa produced from the wild-type allele. Re-
cent studies have suggested that alleles of as many as
half of all genes examined exhibit 2–4 fold allelic var-
iation in expression and that this characteristic segre-
gates with the alleles from one generation to the next
(Yan et al. 2002; Lo et al. 2003). If this is the case for
MCCA, then the expression level of the wild-type allele
would be an additional variable affecting the conse-
quences of heterozygosity for a nonfunctional allele. A
heterozygote with a low-expression wild-type allele
might be clinically and/or biochemically symptomatic.
Conversely, a heterozygote with a high-expression wild-
type allele would be normal. However, our allelic ex-
pression studies showed approximately equal expres-
sion of both alleles in patient MCC047 and his mother.
In patient MCC048, we found slightly reduced expres-
sion of the MCCA-R385S allele (marked by P464) as
compared with the wild-type allele (ﬁg. 4). This result
may explain the less severe biochemical abnormalities
and clinical phenotype in this patient.
Additional factors that could inﬂuence the phenotypic
consequences of MCC deﬁciency include the extent to
which the pathway is stressed by dietary or other en-
vironmental factors (e.g., excessive protein breakdown
associated with an intercurrent infection). In this regard,
the father of patient MCC047 is described as being
healthy during infancy and childhood. Finally, normal
variation in genes whose protein products have the po-
tential to modify the function of MCC or the demands
on the pathway could also inﬂuence the phenotype of
MCC deﬁciency. MCCB and HCS are obvious candi-
date modiﬁer genes for MCCA, but we found no se-
quence variation in either of these genes in our patients.
It is surprising that the clinical symptoms in patient
MCC047 and the biochemical phenotype in both pa-
tients appeared to respond to high doses of biotin. A
biotin-responsive form of MCC deﬁciency has not been
reported elsewhere (Sweetman and Williams 2001),
even in Germany, where MCCA-R385S appears to be
a common allele. In part, this may be because of failure
to administer high doses of biotin on the order of 2–5
mg/kg/d. Biotin responsiveness in our patients is con-
sistent with the observation that MCCA-R385S pro-
duces a stable protein and that other cofactor-responsive
disorders are allele speciﬁc (e.g., cystathione b-synthase)
(Mudd et al. 2001). It also agrees with the ﬁndings of
Sloane and Waldrop (2004), who showed that biotin
decreases the negative cooperativity of E. coli biotin
carboxylase with a missense mutation in the residue
corresponding toMCCA-R385S. Alternatively, a biotin-
dependent increase in the level of MCCA mRNA also
could explain biotin responsiveness. A regulatory role
for biotin in the control ofHCS and carboxylasemRNA
levels through a signaling pathway that requires HCS,
guanylate cyclase, and cGMP-dependent protein kinase
has recently been proposed (Solorzano-Vargas et al.
2002). To provide further evidence for biotin respon-
siveness in our patients, additional clinical, biochemical,
and molecular studies in patients with biotin versus
without biotin would be useful. This was not possible,
however, because of parental unwillingness (for patient
MCC047) and ethical considerations regarding the
asymptomatic patient MCC048. For the future, we rec-
ommend careful documentation of the consequences of
biotin administration in newly diagnosed patients, es-
pecially those carrying the MCCA-R385S allele.
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